Current issues of pathogenesis, diagnostic visualization and methods of treatment Peyronie’s disease

Cover Page

Cite item

Full Text

Abstract

This paper presents current survey data on the epidemiology, etiopathogenesis, diagnostic imaging, conservative and surgical methods of the treatment for Peyronie’s disease. The review of literature ends with a conclusion that there is no single point of view on causes and mechanisms of this disease. Particular theories of etiopathogenesis were observed: anatomical, autoimmune, genetic, oxidative stress theories and TGF-β impact role. Early diagnosis is necessary to achieve optimal effects of the treatment. Sonography with or without cavernosography are recommended as routine diagnostic visualization methods. Magnetic resonance imaging also could be used according to the indications. Morphometric penile evaluation could be performed with different modern methods; quantitative assessment has a particular role. In addition, comparative characteristics of diagnostic imaging methods were described. Among nonsurgical therapeutic methods, we spotted peroral, injection and shock wave therapy. Peroral therapy does not impact plaque size and penile curvature and should be used only in active phase to stabilize the process. Shock wave therapy does not affect plaque size as well, but has a positive effect on pain syndrome and erectile function. Injection therapy with collagenase clostridium histolyticum is the most effective method among nonsurgical ones. Main surgical techniques such as plication, grafting, penile prosthesis placement and also rehabilitation in postoperative period were observed in this review. Surgery maintains to be golden standard in Peyronie’s disease and is performed in patients with stable phase, as well as in patients with severe deformity and with drug-refractory condition.

About the authors

B. G. Kasenova

Urological department of Khanty-mansiysk Autonomous Region-Ugra Nizhnevartovsk clinical hospital

Author for correspondence.
Email: verdievrafik@gmail.com
Nizhnevartovsk, Russian Federation

I. K. Notov

Novosibirsk State Medical University

Email: verdievrafik@gmail.com
Novosibirsk, Russian Federation

R. V. Verdiev

Pirogov Medical University

Email: verdievrafik@gmail.com
Moscow, Russian Federation

D. I. Volobuev

The International Tomography Center of the Siberian Branch of the Russian Academy of the Sciences

Email: verdievrafik@gmail.com
Novosibirsk, Russian Federation

U. M. Aliev

Burnazyan Federal Medical Biophysical Center

Email: verdievrafik@gmail.com
Moscow, Russian Federation

S. E. Mikailova

Novosibirsk State Medical University

Email: verdievrafik@gmail.com
Novosibirsk, Russian Federation

A. A. Erkovich

Novosibirsk State Medical University

Email: verdievrafik@gmail.com
Novosibirsk, Russian Federation

A. A. Tulupov

The International Tomography Center of the Siberian Branch of the Russian Academy of the Sciences

Email: verdievrafik@gmail.com
Novosibirsk, Russian Federation

A. V. Satinov

Urological department of Khanty-mansiysk Autonomous Region-Ugra Nizhnevartovsk clinical hospital

Email: verdievrafik@gmail.com
Nizhnevartovsk, Russian Federation

References

  1. Schepelev P.A. et al. Clinical recommendations peyroni’s disease. Andrology and genital surgery. 2007; 1 : 55—8.
  2. Hellstrom W.J. G. et al. Self-report and clinical response to peyronie’s disease treatment: peyronie’s disease questionnaire results from 2 large double-blind, randomized, placebo-controlled phase 3 studies. Urology. 2015; 86(2) : 291—9.
  3. Mulhall J.P. et al. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening.The Journal of urology. 2004; 171(6); 2350—3.
  4. Dolmans G.H. et al. WNT2 locus is involved in genetic susceptibility of Peyronie’s disease. The journal of sexual medicine. 2012; 9(5) : 1430—4.
  5. Lue, T.F. Peyronie’s disease. An anatomically-based hypothesis and beyond / T.F. Lue. International Journal of Impotence Research. 2002;14: 411—3.
  6. Bivalacqua T.J. et al. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie’s'like condition in the rat.Journal of andrology. 2001;22(3):497—506.
  7. Stewart S. et al. Increased serum levels of anti-elastin antibodies in patients with Peyronie’s disease. The Journal of urology. 1994;152(1):105—6.
  8. Balza E. et al. Transforming growth factor β regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS letters. 1988; 228(1):42—4.
  9. Cantini L.P. et al. Profibrotic role of myostatin in Peyronie’s disease. The journal of sexual medicine. 2008;5(7):1607— 22.
  10. El-Sakka A.I. et al. The pathophysiology of Peyronie’s disease. Arab journal of urology. 2013; 11(3): 272—7.
  11. Bertolotto M., Coss M., Neumaier C.E. US evaluation of patients with Peyronie’s disease. Color Doppler US of the Penis. Springer, Berlin, Heidelberg, 2008. p 61—69.
  12. Chen J.Y., Hockenberry M.S., Lipshultz L.I. Objective assessments of Peyronie’s disease. Sexual medicine reviews. 2018; 6(3):438—45.
  13. Montorsi F. et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie’s disease. The Journal of urology. 2000;163(6):1704—8.
  14. Andresen R, Wegner HE, Miller K, Banzer D. Imaging modalities in Peyronie, s disease. An intrapersonal comparison of ultrasound sonography, X-ray in mammography technique, computerized tomography, and nuclear magnetic resonance in 20 patients. EurUrol 1998; 34:128—34; discussion 135.
  15. Kalokairinou K. et al. US imaging in Peyronie’s disease. Journal of clinical imaging science. 2012; 2:22—8.
  16. Hauck E.W. et al. Diagnostic value of magnetic resonance imaging in Peyronie’s disease — a comparison both with palpation and ultrasound in the evaluation of plaque formation. European urology. 2003; 43(3):293—300.
  17. Alyaev Y.G. et al. Combinated therapy of fibroplastic induction of the penis. Andrology and Genit. surgery. 2003; 2:41—2.
  18. Alhammadi A. et al. The utility of MRI of the penis in the management of Peyronie disease. European Urology Supplements. 2018; 17(2): e1311-e1312.
  19. Parker III R. A. et al. MR imaging of the penis and scrotum. Radiographics. 2015; 35(4):1033—50.
  20. Pretorius E.S. et al. MR imaging of the penis. Radiographics. 20019; 21. suppl_1: S283-S298.
  21. Bertolotto M. et al. Painful penile induration: imaging findings and management. Radiographics. 2009; 29(2):477—93.
  22. Tu L.H. et al. MRI of the penis: indications, anatomy, and pathology. Current problems in diagnostic radiology. 2018. p.156.
  23. Sirikci A. et al. Penile epithelioid sarcoma: MR imaging findings. European radiology. 1999; 9(8):1593—95.
  24. Vossough A., Pretorius E.S., Siegelman E.S., Ramchandani P., Banner M.P. Magnetic resonance imaging of the penis. Abdom Imaging 2002; 27:640—59.
  25. Wang H.J. et al. Diagnostic value of high-field MRI for Peyronie’s disease. Zhonghua nan ke xue= National journal of andrology. 2016; 22(9):787—91.
  26. Jordan G.H., Angermeier K.W. Preoperative evaluation of erectile function with dynamic infusion cavernosometry/ cavernosography in patients undergoing surgery for Peyronie’s disease: Correlation with postoperative results. J Urol 1993; 150:1138—42.
  27. Chen T.Y., Zahran A.R., Carrier S. Penile curvature associated with scleroderma. Urology 2001; 58:282—6.
  28. Nehra A. et al. Peyronie’s disease: AUA guideline.The Journal of urology. 2015; 194(3):745—53.
  29. Hsi R.S. et al. Validity and Reliability of a Smartphone Application for the Assessment of Penile Deformity in P eyronie’s Disease.The journal of sexual medicine. 2013; 10(7):1867—73.
  30. Margolin E.J. et al. Three-dimensional photography for quantitative assessment of penile volume-loss deformities in Peyronie’s disease. The journal of sexual medicine. 2017;14(6):829—33.
  31. Teloken C. et al. Tamoxifen versus placebo in the treatment of Peyronie’s disease. The Journal of urology. 1999; 162(6):2003—5.
  32. Safarinejad M.R., Hosseini S.Y. and Kolahi A.A.: Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie’s disease: a double-blind, placebo controlled, randomized study. J Urol. 2007; 178:4 Pt 11398.
  33. Bystrom J.: Induration penis plastica. Experience of treatment with procarbazine Natulan. Scand J Urol Nephrol. 1976; 10: 121—5.
  34. Hauck E.W. et al. A critical analysis of nonsurgical treatment of Peyronie’s disease. European Urology. 20069; 49(6):987—97.
  35. Palmieri A. et al. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. International journal of andrology. 2012; 35(2):190—5.
  36. Weidner W., Hauck E.W., Schnitker J. For the Peyronie’s Disease Study Group of German Urologists, authors. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005; 47:530—5.
  37. Ralph D., Gonzalez-Cadavid N., Mirone V., et al. The management of Peyronie’s disease: EVIDENCE-based 2010 guidelines. J Sex Med. 2010; 7(7):2359—2374.
  38. Serefoglu E.C., Hellstrom W.J. Treatment of Peyronie’s disease: 2012 update. Curr Urol Rep. 2011; 12:444—452.
  39. Duncan M.R., Berman B., Nseyo U.O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha,-beta andgamma. Scandinavian journal of urology and nephrology. 1991;25(2):89—94.
  40. Hellstrom W.J. G. et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon α-2b for minimally invasive treatment for Peyronie’s disease. The Journal of urology. 2006; 176(1):394—8.
  41. Inal T., Tokatli Z., Akand M., Ozdiler E., Yaman O. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie’s disease: a randomized and prospective study. Urology. 2006; 67:1038—42.
  42. Kendirci M. et al. The Impact of Intralesional Interferon α2b Injection Therapy on Penile Hemodynamics in Men with Peyronie’s Disease.The journal of sexual medicine. 2005; 2(5):709—15.
  43. Gelbard M. et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. The Journal of urology. 2013; 190(1):199—207.
  44. Gelbard M. et al. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie’s disease. The journal of sexual medicine. 2013;10(11):2822—31.
  45. Gelbard M., Lipshultz L.I., Tursi J., Smith T., Kaufman G., Levine L.A. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012; 187:2268—2274.
  46. Rehman J., Benet A. and Melman A.: Use of intralesional verapamil to dissolve Peyronie’s disease plaque: a longterm single-blind study. Urology. 1998; 51: 4620—5.
  47. Shirazi M., Haghpanah A.R., Badiee M. et al: Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009; 41: 3467—71.
  48. Pendleton C., Wang R. Peyronie’s disease: current therapy. Transl Androl Urol. 2013;2(3):15—23.
  49. Hauck E.W., Mueller U.O., Bschleipfer T., Schmelz H.U., Diemer T., Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol. 2004; 171(2 pt 1): 740—5.
  50. Nehra A., Alterowitz R., Culkin D.J., et al; American Urological Association Education and Research, Inc. Peyronie’s disease: AUA guideline. J Urol. 2015; 194(3):745—53.
  51. Palmieri A., Imbimbo C., Longo N., et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009; 56(2):363—70.
  52. Ralph D., Gonzalez-Cadavid N., Mirone V., et al. The management of Peyronie’s disease: EVIDENCE-based 2010 guidelines. J Sex Med. 2010; 7(7):2359—74.
  53. Hamidov S.I. et al. Long-term results of corporoplasty in Peyronie’s disease. Andrology and genital surgery. 2018; 19(4):39—45.
  54. Rehman J. et al. Results of surgical treatment for abnormal penile curvature: Peyronie’s disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). The Journal of urology. 1997; 157(4):1288—91.
  55. Serefoglu E.C., Hellstrom W.J.G. Treatment of Peyronie’s disease: 2012 update.Current urology reports. 2011; 12(6):444—52.
  56. Gholami S.S., Lue T.F. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. The Journal of urology. 2002; 167(5):2066—9.
  57. Kalinina S.N. et al. Surgical treatment of Peyronie’s disease. Urological statements. 2018; 8(2):22—8. (In Russ.)
  58. Ralph D. et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. The journal of sexual medicine. 2010;7(7):2359—74.
  59. Egydio P.H., Lucon A.M., Arap S. A single relaxing incision to correct different types of penile curvature: surgical technique based on geometrical principles. BJU international. 2004;94(7):1147—57.
  60. Chung E. et al. Evidence-based management guidelines on Peyronie’s disease. The journal of sexual medicine. 2016;13(6):905—23.
  61. Garaffa G. et al. Long-term results of reconstructive surgery for Peyronie’s disease. Sexual medicine reviews. 2015; 3(2):113—21.
  62. Chung E. et al. Five year follow up of Peyronie’s graft surgery: Outcomes and patient satisfaction. The journal of sexual medicine. 2011; 8(2):594—600.
  63. Brant W.O. et al. Surgical Atlas Correction of Peyronie’s disease: plaque incision and grafting. BJU international. 2006;97(6):1353—60.
  64. Levine L.A., Burnett A.L. Standard operating procedures for Peyronie’s disease. The journal of sexual medicine. 2013; 10(1):230—44.
  65. Gamidov S.I. et al. A new type of shock wave therapy (linear) in the treatment of severe forms of erectile dysfunction (pilot study). Farmateka. 2016; 3;84—7 (In Russ.).
  66. Tereshin A.T., Nedelko D.E., Lazarev I.L. Shock wave therapy in the treatment of patients with chronic prostatitis with erectile dysfunction. Bulletin of new medical technologies. Electronic edition. 2014. № 1 (In Russ.)

Copyright (c) 2020 Kasenova B.G., Notov I.K., Verdiev R.V., Volobuev D.I., Aliev U.M., Mikailova S.E., Erkovich A.A., Tulupov A.A., Satinov A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies